A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing
| Autor: | Lawrence B. Cohen, Neville D. Bamji, Jay Desai, C. Von Althann, A. Dikman, Andrew Brooks, S. Sanyal, Carol A. Bodian, James Aisenberg, Kenneth M. Miller, Matthew J. Whitson |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Peptic Ulcer Ticlopidine Analgesic Placebo-controlled study Pilot Projects Placebo Drug Administration Schedule Lesion Young Adult Naproxen medicine Humans Pharmacology (medical) Antipyretic Aged Sulfonamides Aspirin Hepatology business.industry Anti-Inflammatory Agents Non-Steroidal Gastroenterology Middle Aged Clopidogrel Celecoxib Gastric Mucosa Anesthesia Pyrazoles Female medicine.symptom business medicine.drug |
| Zdroj: | Alimentary Pharmacology & Therapeutics. 29:781-791 |
| ISSN: | 1365-2036 0269-2813 |
| Popis: | Summary Background Many individuals with gastroduodenal ulcers require on-going, non-steroidal anti-inflammatory drug (NSAID) or anti-platelet therapy. Aims To evaluate the effects of these agents on gastroduodenal mucosal healing. Methods Helicobacter pylori-negative volunteers were randomized to receive naproxen, celecoxib, aspirin, clopidogrel or placebo. Antral and duodenal lesions were created endoscopically with a biopsy forceps. After 7 days of medication dosing, each lesion was scored [from 0 (low) to 8 (high)] using a validated methodology. The primary endpoint was the mean injury score. The secondary endpoint was the percentage of subjects with ≥1 unhealed lesion. Results In all, 108 subjects completed the study. Naproxen impaired antral lesion healing more than placebo, clopidogrel, aspirin or celecoxib (mean injury score of 4.3 vs. 3.0, 2.7, 3.2, and 3.2, respectively, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |